The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice
Open accessAbstract
Significance: Despite its success in treating hematological cancers, chimeric antigen receptor (CAR) T cell therapy does not so easily eliminate solid tumors. Solid tumors generally develop in a highly immunosuppressive environment and are difficult to target, mostly due to a lack of tumor-specific antigen expression, but other factors contribute as well. This study develops a strategy to target multiple solid tumor types through markers in their microenvironment. The use of single-domain antibody (VHH)-based chimeric antigen receptor (CAR) T cells that recognize these markers circumvents the need for tumor-specific targets. VHH-based CAR T cells that target the tumor microenvironment through immune checkpoint receptors or through stroma and ECM markers are effective against solid tumors in syngeneic, immunocompetent animal models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
The Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., & Gately, M. K. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.4.1223 · Cited by 1,197
Hallmarks of cancer: Interactions with the tumor stroma
Pietras, K., & Östman, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.02.045 · Cited by 1,141
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757
Neri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Modulation of protein properties in living cells using nanobodies
Kirchhofer, A., Helma, J., Schmidthals, K., Frauer, C., Cui, S., Karcher, A., Pellis, M., Muyldermans, S., Casas-Delucchi, C. S., Cardoso, M. C., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1727 · Cited by 586
Vincke, C., Loris, R., Saerens, D., Martinez-Rodriguez, S., Muyldermans, S., & Conrath, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806889200 · Cited by 572
Craddock, J. A., Lu, A., Bear, A., Pule, M., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6675 · Cited by 513
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 508
Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 487
Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A. K., Dentchev, T., Thekkat, P., Loew, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4963 · Cited by 454
Nanobody-based products as research and diagnostic tools
De Meyer, T., Muyldermans, S., & Depicker, A. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.03.001 · Cited by 445
Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor
Wilkie, S., Picco, G., Foster, J., Davies, D. M., Julien, S., Cooper, L., Arif, S., Mather, S. J., Taylor-Papadimitriou, J., Burchell, J. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4901 · Cited by 346
Immune microenvironments in solid tumors: new targets for therapy
Shiao, S. L., Ganesan, A. P., Rugo, H. S., & Coussens, L. M. (2011) · Genes & Development · doi:10.1101/gad.169029.111 · Cited by 322
The fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesis
Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G., & Zardi, L. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590507 · Cited by 316
Nanobodies as novel agents for cancer therapy
Revets, H., De Baetselier, P., & Muyldermans, S. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.111 · Cited by 254
Exploiting Nanobodies’ Singular Traits
Ingram, J. R., Schmidt, F. I., & Ploegh, H. L. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053327 · Cited by 254
Self-citationFong, L., Kwek, S. S., O'Brien, S., Kavanagh, B., McNeel, D. G., Weinberg, V., Lin, A. M., Rosenberg, J., Ryan, C. J., Rini, B. I., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3529 · Cited by 246
Gong, M. C., Latouche, J.-B., Krause, A., Heston, W. D. W., Bander, N. H., & Sadelain, M. (1999) · Neoplasia · doi:10.1038/sj.neo.7900018 · Cited by 241
Zhao, Y., Harrison, D. L., Song, Y., Ji, J., Huang, J., & Hui, E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.054 · Cited by 188
Jailkhani, N., Ingram, J. R., Rashidian, M., Rickelt, S., Tian, C., Mak, H. H., Jiang, Z.-G., Ploegh, H. L., & Hynes, R. O. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817442116 · Cited by 158
Self-citationWörn, A., & Plückthun, A. (1999) · Biochemistry · doi:10.1021/bi9902079 · Cited by 140
Localized CD47 blockade enhances immunotherapy for murine melanoma
Ingram, J. R., Blomberg, O. S., Sockolosky, J. T., Ali, L. R., Schmidt, F. I., Pishesha, N., Espinosa, C. A., Dougan, S. K., García, K. C., Ploegh, H. L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710776114 · Cited by 139
Self-citationPD-L1 is an activation-independent marker of brown adipocytes
Ingram, J. R., Dougan, M. L., Rashidian, M., Knoll, M., Keliher, E. J., Garrett, S., Garforth, S., Blomberg, O. S., Espinosa, C. A., Bhan, A. K., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00799-8 · Cited by 133
Self-citationNanobody Based Dual Specific CARs
Munter, S. D., Ingels, J., Goetgeluk, G., Bonte, S., Pille, M., Weening, K., Kerre, T. C. C., Abken, H., & Vandekerckhove, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020403 · Cited by 128
Mechanisms of melanogenesis inhibition by tumor necrosis factor‐α in B16/F10 mouse melanoma cells
Martinez‐Esparza, M., Jiménez‐Cervantes, C., Solano, F., Lozano, J. A., & García-Borrón, J. C. (1998) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1998.2550139.x · Cited by 124
Astrof, S., Crowley, D. G., George, E. L., Fukuda, T., Sekiguchi, K., Hanahan, D., & Hynes, R. O. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8662-8670.2004 · Cited by 112
Self-citationTargeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs
Dougan, M. L., Ingram, J. R., Jeong, H., Mosaheb, M. M., Bruck, P. T., Ali, L. R., Pishesha, N., Blomberg, O. S., Tyler, P. M., Servos, M. M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0495 · Cited by 95
Self-citationSun, W., Xie, J., Lin, H., Mi, S., Li, Z., Hua, F., & Hu, Z. (2012) · Protein Expression and Purification · doi:10.1016/j.pep.2012.02.006 · Cited by 71
Allosteric activation of apicomplexan calcium-dependent protein kinases
Ingram, J. R., Knockenhauer, K. E., Markus, B. M., Mandelbaum, J., Ramek, A., Shan, Y., Shaw, D. E., Schwartz, T., Ploegh, H. L., & Lourido, S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505914112 · Cited by 60
Self-citationKhaleghi, S., Rahbarizadeh, F., Ahmadvand, D., Rasaee, M. J., & Pognonec, P. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1037-6 · Cited by 45
Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by PhiC31 integrase
Sofla, F. J. I., Rahbarizadeh, F., Ahmadvand, D., & Rasaee, M. J. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.08.015 · Cited by 43
Utilizing nanobody technology to target non-immunodominant domains of VAR2CSA
Ditlev, S. B., Florea, R., Nielsen, M. A., Theander, T. G., Magez, S., Boeuf, P., & Salanti, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084981 · Cited by 31
Cheung, N. V., Guo, H.-F., Modak, S. I., & Cheung, I. Y. (2003) · Hybridoma and Hybridomics · doi:10.1089/153685903322328938 · Cited by 26
Ting, C., & Yang, S. S. (1982) · International Journal of Cancer · doi:10.1002/ijc.2910300513 · Cited by 11
Cited by
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Cox, T. R. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00329-7 · Cited by 976
Modulating extracellular matrix stiffness: A strategic approach to boost cancer immunotherapy
Mai, Z., Lin, Y., Lin, P., Zhao, X., & Cui, L. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06697-4 · Cited by 398
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner, J., Wickman, E., DeRenzo, C., & Gottschalk, S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 380
CAR-T design: Elements and their synergistic function
Jayaraman, J., Mellody, M. P., Hou, A. J., Desai, R. P., Fung, A. W., Pham, A. H. T., Chen, Y. Y., & Zhao, W. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102931 · Cited by 374
Metadata
- Authors
- Xie, Y. J., Dougan, M., Jailkhani, N., Ingram, J., Fang, T., Kummer, L., Momin, N., Pishesha, N., Rickelt, S., Hynes, R. O., & Ploegh, H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2019-04
- Volume
- 116
- Issue
- 16
- Pages
- 7624-7631
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2927684362
- Cited by
- 296
- References
- 46
- FWCI
- 15.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.